KNBIF (Kane Biotech) Cyclically Adjusted Price-to-FCF: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kane Biotech Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kane Biotech  (OTCPK:KNBIF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Kane Biotech Cyclically Adjusted Price-to-FCF Related Terms


Kane Biotech Cyclically Adjusted Price-to-FCF Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Cyclically Adjusted Price-to-FCF Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KNBIF vs VRTX, REGN, MRNA: Cyclically Adjusted Price-to-FCF Comparison

For the Biotechnology subindustry, Kane Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Cyclically Adjusted Price-to-FCF falls into.



Kane Biotech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Kane Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Kane Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.002/132.2623*132.2623
=-0.002

Current CPI (Mar. 2026) = 132.2623.

Kane Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.025 102.002 -0.032
201609 -0.014 101.765 -0.018
201612 -0.011 101.449 -0.014
201703 -0.003 102.634 -0.004
201706 -0.012 103.029 -0.015
201709 -0.009 103.345 -0.012
201712 -0.005 103.345 -0.006
201803 -0.007 105.004 -0.009
201806 -0.009 105.557 -0.011
201809 -0.006 105.636 -0.008
201812 -0.007 105.399 -0.009
201903 -0.004 106.979 -0.005
201906 0.013 107.690 0.016
201909 -0.009 107.611 -0.011
201912 -0.009 107.769 -0.011
202003 -0.011 107.927 -0.013
202006 -0.003 108.401 -0.004
202009 -0.002 108.164 -0.002
202012 -0.013 108.559 -0.016
202103 -0.003 110.298 -0.004
202106 -0.008 111.720 -0.009
202109 -0.006 112.905 -0.007
202112 -0.001 113.774 -0.001
202203 -0.006 117.646 -0.007
202206 -0.005 120.806 -0.005
202209 -0.006 120.648 -0.007
202212 -0.003 120.964 -0.003
202303 -0.006 122.702 -0.006
202306 0.002 124.203 0.002
202309 -0.004 125.230 -0.004
202312 -0.005 125.072 -0.005
202403 -0.006 126.258 -0.006
202406 -0.010 127.522 -0.010
202409 -0.003 127.285 -0.003
202412 -0.002 127.364 -0.002
202503 -0.007 129.181 -0.007
202506 -0.003 129.892 -0.003
202509 -0.003 130.287 -0.003
202512 -0.003 130.366 -0.003
202603 -0.002 132.262 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.